The Therapeutic Effectiveness of Full Spectrum Hemp Oil Using a Chronic Neuropathic Pain Model Jacob M. Vigil, Marena A. Montera, Nathan S. Pentkowski, Jegason P. Diviant, Joaquin Orozco, Anthony L. Ortiz, Lawrence J. Rael and Karin N. Westlund Life, 2020, 10, 69, 1-12 doi : 10.3390/life10050069 Abstract : Background : Few models exist that can control for placebo and expectancy effects commonly observed in clinical trials measuring ‘Cannabis’ pharmacodynamics. We used the Foramen Rotundum Inflammatory Constriction Trigeminal Infraorbital Nerve injury (FRICT-ION) model to measure the effect of “full-spectrum” whole plant extracted hemp oil on chronic neuropathic pain sensitivity in mice. Methods : Male BALBc mice were [...]
Lire la suiteDeveloping Robust Standardised Analytical Procedures for Cannabinoid Quantification : Laying the Foundations for an Emerging Cannabis-Based Pharmaceutical Industry Matthew T. Welling, Lei Liu, Arno Hazekamp, Ashley Dowell, Graham J. King Medical Cannabis & Cannabinoids, 2019, 2, 1–13 Doi : 10.1159/000496868 Abstract The plant genus Cannabis is a prolific producer of unique pharmaceutically relevant metabolites, commonly referred to as cannabinoids. Robust and standardised methods for the quantification of cannabinoids within botanical and drug forms is a critical step forward for an emerging Cannabis- based pharmaceutical industry, which is poised for rapid expansion. Despite a growing body of analytical methods for the quantification of cannabinoids, few have [...]
Lire la suiteA Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers Daniel Perkins · Juliet Butler · Katherine Ong · Tri‑Hung Nguyen · Susan Cox · Barbara Francis · Michelle Mcintosh · Brian Lilley European Journal of Drug Metabolism and Pharmacokinetics, 2020, Doi : 10.1007/s13318-020-00624-6 Abstract Background : There is increasing interest in the use of purified cannabidiol (CBD) as a treatment for a wide range of conditions due to its reported anti-inflammatory, anxiolytic, antiemetic and anticonvulsant properties. Objective : The objective of this study was to assess the [...]
Lire la suiteAltered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment Tibor Stark, Martina Di Bartolomeo, Roberta Di Marco, Eva Drazanova, Chiara Bianca Maria Platania, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Claudio D'Addario, Lucie Kratka, Vladimir Pekarik, Fabiana Piscitelli, Zuzana Babinska, Julia Fedotova, Giovanni Giurdanella, Salvatore Salomone, Alexandra Sulcova, Claudio Bucolo, Carsten T.Wotjak, Zenon Starcuk Jr, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Micale Biochemical Pharmacology, April 2020, 1-12. doi : 10.1016/j.bcp.2020.114004 Un excellent article international (République Tchèque, Allemagne, Italy, Russie, Israel, Canada), avec la plus grande plume de la recherche sur les cannabinoïdes (Mechoulam, Di Marzo...) qui [...]
Lire la suiteCannabinol inhibits proliferation and induces cell cycle arrest and apoptosis in glioblastoma, hepatocellular carcinoma and breast cancer cells Nuanying ZHONG, Thesis, Master of Science in Biological Sciences Faculty of Arts and Science, Department of Biological Sciences, University of Lethbridge Research Repository, Canada 2020 https://hdl.handle.net/10133/5697 ABSTRACT Cannabis sativa is an agriculturally and medicinally plant with many pharmaceutical properties. Cancer is a deadly disease; it is estimated that it will cause over 80 thousand deaths in 2019 in Canada. Although numerous studies have demonstrated that cannabinoids have anti-tumorous properties in various cancers, the anti-malignant activities of cannabinol (CBN) on carcinogenesis and underlying mechanisms remain largely unknown. In this study, we [...]
Lire la suiteCBD Reverts the Mesenchymal Invasive Phenotype of Breast Cancer Cells Induced by the Inflammatory Cytokine IL-1 Lázaro García-Morales, Aída M Castillo, José Tapia Ramírez, Horacio Zamudio-Meza, Ma del Carmen Domínguez-Robles and Isaura Meza International Journal of Molecular Science, 2020, 21, 2429 doi : 10.3390/ijms21072429 Abstract : Cannabidiol (CBD) has been used to treat a variety of cancers and inflammatory conditions with controversial results. In previous work, we have shown that breast cancer MCF-7 cells, selected by their response to inflammatory IL-1 cytokine, acquire a malignant phenotype (6D cells) through an epithelial mesenchymal transition (EMT).We evaluated CBD as a potential inhibitor of this transition and inducer of [...]
Lire la suiteCannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia Fernanda F. Peres, Mariana C. Diana, Raquel Levin, Mayra A. Suiama, Valéria Almeida, Ana M. Vendramini, Camila M. Santos, Antônio W. Zuardi, Jaime E. C. Hallak, José A. Crippa and Vanessa C. Abílio Frontiers in Pharmacology, 2018, 9, article 901. Doi : 10.3389/fphar.2018.00901 Schizophrenia is considered a debilitating neurodevelopmental psychiatric disorder and its pharmacotherapy remains problematic without recent major advances. The development of interventions able to prevent the emergence of schizophrenia would therefore represent an enormous progress. Here, we investigated whether treatment with cannabidiol (CBD – a compound of Cannabis sativa that [...]
Lire la suiteLE CBD EST-IL PSYCHOACTIF ? François-Olivier GAGNON-HÉBERT – Chercheur Postdoctoral/ Université de Moncton, Canada La Lettre du RESPADD, 2019, 36, 4-5 https://www.respadd.org/lettre-n36-octobre-2019/ Il semble y avoir une véritable résurgence du cannabis dans les débats publics à l’échelle internationale depuis quelques années. Cette plante cultivée depuis les premiers balbutiements des sociétés humaines néolithiques grégaires (Warf 2014) ne laisse personne indifférent. Bien que les apologistes et les détracteurs de l’usage de la plante ne s’entendent généralement sur aucun point, tous s’entendent sur la réalité suivante : il s’agit d’une question fort complexe et épineuse. Au-delà des débats moraux et sociétaux, il n’en demeure pas moins que le cannabis [...]
Lire la suiteEtats-Unis : l’Epidiolex n’est plus une substance contrôlée Aurélien BERNARD Newsweed.fr, 8 avril 2020 https://www.newsweed.fr/etats-unis-lepidiolex-nest-plus-une-substance-controlee/ GW Pharmaceuticals a annoncé lundi que l’Epidiolex, un médicament à base de cannabidiol (CBD) utilisé dans le traitement de l’épilepsie, avait été retiré de l’annexe V de la Loi américaine sur les substances contrôlées par la Drug Enforcement Administration (DEA). Les personnes qui pourraient en bénéficier pourront dorénavant en obtenir plus facilement. GW a déclaré dans son communiqué qu’il « entamera maintenant le processus de mise en œuvre de ces changements au niveau de l’État et via le réseau de distribution EPIDIOLEX ». Comme pour de nombreux médicaments non-contrôlés, les malades ou leurs [...]
Lire la suiteBibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, avril 2020. voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives
Lire la suite